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Abstract
Serine-threonine protein kinases are critical to CNS function, yet there is a dearth of highly selective, CNS-active kinase
inhibitors for in vivo investigations. Further, prevailing assumptions raise concerns about whether single kinase inhibitors
can show in vivo efficacy for CNS pathologies, and debates over viable approaches to the development of safe and
efficacious kinase inhibitors are unsettled. It is critical, therefore, that these scientific challenges be addressed in order to test
hypotheses about protein kinases in neuropathology progression and the potential for in vivo modulation of their catalytic
activity. Identification of molecular targets whose in vivo modulation can attenuate synaptic dysfunction would provide a
foundation for future disease-modifying therapeutic development as well as insight into cellular mechanisms. Clinical and
preclinical studies suggest a critical link between synaptic dysfunction in neurodegenerative disorders and the activation of
p38aMAPK mediated signaling cascades. Activation in both neurons and glia also offers the unusual potential to generate
enhanced responses through targeting a single kinase in two distinct cell types involved in pathology progression.
However, target validation has been limited by lack of highly selective inhibitors amenable to in vivo use in the CNS.
Therefore, we employed high-resolution co-crystallography and pharmacoinformatics to design and develop a novel
synthetic, active site targeted, CNS-active, p38aMAPK inhibitor (MW108). Selectivity was demonstrated by large-scale
kinome screens, functional GPCR agonist and antagonist analyses of off-target potential, and evaluation of cellular target
engagement. In vitro and in vivo assays demonstrated that MW108 ameliorates beta-amyloid induced synaptic and
cognitive dysfunction. A serendipitous discovery during co-crystallographic analyses revised prevailing models about active
site targeting of inhibitors, providing insights that will facilitate future kinase inhibitor design. Overall, our studies deliver
highly selective in vivo probes appropriate for CNS investigations and demonstrate that modulation of p38aMAPK activity
can attenuate synaptic dysfunction.
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Introduction
An evolving view of progressive neurodegenerative disorders
such as Alzheimer’s disease (AD), frontotemporal dementia, and
Parkinson’s disease is their potential to be approached as diseases
of progressive synaptic dysfunction [1–3]. Considerable clinical
and preclinical studies suggest a critical link between the synaptic
dysfunction in neurodegenerative disorders and activation of
p38MAPK signaling cascades in both neurons and glia [4,5].
Mammals have four different genes that encode distinct p38
MAPK isoforms (p38a, p38b, p38c, p38d) with high sequence
similarity (e.g, p38a has approximately 75% sequence identity to
p38b). The four p38MAPK isoforms are widely expressed and
selectively initiate downstream responses dependent on the cell
type and the activating stimulus. In neurodegenerative disease
models, specific p38MAPK signaling cascades involving substrates
such as MAPKAP-K2 (MK2) and tau have been implicated in
controlling neuroinflammation, neuronal plasticity, and synaptic/
dendritic pathology [4,5]. However, validation of p38aMAPK as a
potential CNS drug discovery target has been limited by the lack
of highly selective p38aMAPK inhibitors amenable to in vivo use in
the CNS.
A variety of small molecules targeting p38MAPKs allowed
pursuit of in vitro studies and in vivo investigations of pathology
progression in some peripheral tissues, but the pharmacokinetics
(what the body does to the molecule) precluded their full use for
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in vivo studies of CNS tissue pharmacodynamics (what the
molecule does to the body). Generally, the molecular properties
of the inhibitors did not allow adequate CNS exposure, thereby
limiting their potential use in CNS investigations [6,7]. In other
studies, interpretation of the pharmacodynamics was hindered by
the multi-kinase nature of the inhibitors [8,9]. For example, there
are literally hundreds of reports using commercially available
inhibitors such as SB239063 and SB203580, but like many
p38aMAPK inhibitors these inhibit casein kinase 1d (CK1d),
p38bMAPK and other kinases [8–10]. Although no selective CNS
penetrant p38aMAPK has yet progressed to human studies, the
ambiguity of results from non-CNS clinical investigations and
preclinical studies raises concerns. For example, an appropriate
pharmacodynamic effect in arthritis investigations was observed
(decrease of proinflammatory cytokine levels back towards
normal), but efficacy in disease alteration was not evident [11].
Although the reasons for the desired but transient pharmacody-
namics with efficacy failure in non-CNS disorders are not known,
diverse mechanisms (e.g., tachyphylaxis) are logical to anticipate in
extended studies where repeat administrations of a pleotropic drug
are involved. Clearly, there is a critical need for selective p38
MAPK inhibitors that are also appropriate for the study of CNS
protein kinases if we are to better understand how regulatory
nodes in complex signaling networks are linked to potential
mechanisms of pathology progression and alteration.
Two current approaches to generate selective small molecule
kinase inhibitors are the allosteric approach, which involves
induction or prevention of enzyme conformational changes via
targeting sites outside the catalytic region, and the active site
approach [12–14]. The allosteric approach is an area of active
investigation that has yet to be generally validated or reduced to
standard practice. The active site approach is that used
successfully to deliver new classes of approved therapeutics and
generate the vast majority of extant molecular probe reagents for
in vivo studies in diverse phylogenetic species. However, the kinase
inhibitors generated by the active site approach, although highly
restrictive in nature, are still generally multi-kinase inhibitors. The
multi-kinase nature and failures with many current kinase
inhibitors have led to a prevailing assumption that efficacy might
not be achievable by targeting a single kinase [15].
This hypothesis has been difficult to test because of the lack of
appropriate inhibitors.
A recently emerging variant of the active site approach focuses
on induction of localized conformational changes by inhibitors in
order to achieve selectivity [16–30]. In the case of p38aMAPK
inhibitors, the approach posits that the common theme of
exploiting hydrogen (H)-bond interactions with the Met109 amide
bond in the phylogenetically conserved kinase hinge region can be
enhanced by designing inhibitors that can also engage the
contiguous Gly110, thereby yielding highly selective inhibitors
that can induce a localized conformational change, termed a
glycine flip. The approach is based on the finding that only a few
kinases have a Gly contiguous to the point of H-bond interaction.
However, the paucity of p38aMAPK inhibitors that lack
problematic cross-over to other serine-threonine kinases, such as
CK1d, and their evaluation by high-resolution crystallography
preclude robust evaluation of such hypotheses as a design strategy.
The p38aMAPK is of neuropharmacology interest as it is
associated with intracellular signal transduction in both glia and
neurons under stresses that are linked to progressive synaptic
dysfunction. Therefore, a highly selective p38aMAPK inhibitor
might be targeting a physiological axis, offering the potential of
pharmacological synergy where dose dependent inhibition of the
same target in each cell type might generate a more robust
response than in other pathophysiology paradigms. As a starting
point for such in vivo investigations, we developed a set of highly
selective inhibitors appropriate for CNS investigations and used
the compounds to implicate p38aMAPK as a potential target for
intervention and attenuation of synaptic dysfunction. The probes
include an isoform-selective p38aMAPK inhibitor, MW01-11-108
( = MW108) and a p38MAPK subfamily inhibitor MW01-10-
181SRM ( = MW181). The high level of selectivity is indicated by
large-scale kinome activity screens, functional GPCR cell-based
evaluation for agonist and antagonist activity, and cellular target
engagement analyses. In vitro and in vivo assays demonstrated the
ability of MW108 and MW181 to ameliorate beta-amyloid
induced synaptic and cognitive dysfunction.
High-resolution crystallographic analysis of human p38aMAPK
in complex with the new selective inhibitors confirmed the active
site targeting and, interestingly, demonstrated the lack of a
detectable glycine flip in the structures. Therefore, control
experiments on the structure of human p38aMAPK with active
site bound SB239063, a mixed-kinase inhibitor, were performed
and demonstrated the glycine flip conformation. The finding that
the less selective p38 inhibitor SB239063 can induce the glycine
flip, whereas MW108 and MW181 do not, indicates that the
ability to induce such a localized conformational change is not a
prerequisite for active site targeted probes with greater specificity.
Overall, the probes described here represent valuable chemical
biology tools for future in vivo investigations, and provide structural
insights that may facilitate future active site targeted inhibitor
design.
.
Materials and Methods
Synthesis of Novel, Selective p38aMAPK Inhibitors
The synthetic scheme and experimental details for the two novel
title compounds, MW01-10-181SRM (MW181) and MW01-11-
108SRM (MW108), are shown in Figure 1 in sufficient detail for
reproduction by one skilled in the art. The design strategy and
synthesis of additional compounds used in the investigation are
presented in Figure S1 and Scheme S1.
Chemicals were purchased from Aldrich (Milwaukee, WI) or
VWR International (Batavia, IL). Solvents were used as received
unless stated otherwise. Water was obtained using a Milli-Q Biocel
A10 purification system from Millipore Corporation (Bedford,
MA). High pressure glassware was from Chemglass, (Vineland,
NJ). All syntheses were monitored by HPLC (Dionex System,
Sunnyvale, CA, with UVD170U ultraviolet detector and P680
pump) on a Phenomenex (Torrance, CA) Luna C18 column
(25062.0 mm; 5 mm; equipped with guard column) at a flow rate
of 0.2 mL/min and using a mobile phase composed of 0.1% (v/v)
formic acid (Fluka) in water as reagent A and 80% acetonitrile,
0.08% formic acid/water as reagent B. Synthetic intermediates
were screened by electrospray mass spectroscopy (ESI) HPLC
(Micromass Quattro II Triple Quadrupole HPLC/MS/MS mass
spectrometer). Final compounds were analyzed by HPLC, high-
resolution mass spectra (HRMS; VG70-250SE mass spectrometer)
and 1H NMR (Bruker Avance-III 500 MHz spectrometer;
ambient temperature). Melting point data for compounds were
acquired on a Bu¨chi Melting Point B-540 (Flawil, Switzerland).
Hydrochloride hydrates (salts) of final compounds were charac-
terized by elemental analysis (Intertek QTI; Whitehouse, NJ).
4-bromo-1,2-dihydropyridazine-3,6-dione (1). Hydrazine
sulfate (2.25 g, 17.2 mmol) was dissolved in boiling water (20 mL)
with stirring. To this solution, bromomaleic anhydride (2.6ml,
28.2 mmol) was added drop wise via addition funnel, the mixture
In Vivo Probes for CNS Protein Kinase Function
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heated (100oC) under reflux for 19 h, then cooled to ambient
temperature. The resulting white precipitate was filtered on a
medium frit sintered glass funnel, washed with acetone (365 ml),
and air dried in vacuo to give the desired product 4-bromo-1,2-
dihydropyridazine-3,6-dione (2.85 g) as a white powder in 87%
yield (gravimetric) with a melting point of 262uC.
4-(pyridin-4-yl)-1,2-dihydropyridazine-3,6-dione (2). Es-
sentially as previously described [31], compound 1 (2 g,
10.4 mmol, 1 eq) and pyridin-4-yl boronic acid (14.3 mmol,
1.76 g, 1.37 eq) were suspended in dimethoxyethane and water
(10:1 v/v) in a heavy wall pressure vessel and purged with argon
for 15 min. Tetrakis (triphenylphosphine) palladium (0.1 eq) and
sodium carbonate (3 eq) were added, the vessel immediately
capped, the reaction mixture heated (110uC ) for 18 h, then cooled
to ambient temperature and subjected to filtration on a medium
frit sintered glass funnel containing CeliteH 545. The filtrate was
concentrated in vacuo and the concentrate triturated with hexane.
The yellow product 2 (2.2 g) exhibited a mass (ESI) of m/z
(MeOH) = 190.06 (MH+), and was taken to the next step without
further purification.
3,6-dichloro-4-(pyridin-4-yl)pyridazine (3). Essentially as
described [32], compound 2 (2.2 g, 11.6 mmol) was suspended in
6.25 ml phosphorus oxychloride in a condenser-fitted round
bottom flask, heated (90uC) for 24 h, cooled to ambient
temperature and volatiles removed in vacuo. The dark residue
was poured onto crushed ice, stirred (2 h), and the mixture
neutralized with saturated sodium carbonate solution. The fine
precipitate was subjected to replicate extraction with dichloro-
methane in a separatory funnel, the combined organic phases
subjected to drying over anhydrous sodium sulfate, concentrated in
vacuo, and subjected to column chromatography on silica gel (200-
400 mesh) using a ethyl acetate:hexane (3:2 v/v) eluent. The
desired product 3 exhibited 97% purity by HPLC and a mass
(ESI) of m/z (MeOH) = 225.99 (MH+). The overall yield (gravi-
metric) from product 1 to 3 was approximately 36%.
6-chloro-N,N-dimethyl-5-(pyridin-4-yl)pyridazin-3-amine
(4). Following published protocol [32], compound 3
(11.06 mmol, 1 eq) in ethanol (60 ml) was placed in a heavy wall
pressure vessel and 40% dimethylamine (6 eq) added, the vessel
capped and heated (110uC) for 16 h, the mixture allowed to cool
to ambient temperature then transferred to a round bottom flask
for concentration in vacuo. The residue was treated with 10 ml of
water, the aqueous phase subjected to replicate extraction with
dichloromethane in a separatory funnel, and the combined
organic layers dried (anhydrous sodium sulfate) and evaporated
under reduced pressure to yield a yellow adherent solid. The
reaction mixture was purified by silica gel (200–400 mesh) column
chromatography and the desired product eluted with ethyl
acetate:hexane (1:1 v/v). Product 4 was obtained as a yellow solid
in 89% (gravimetric) yield, with an apparent HPLC purity of 98%
and a mass (ESI) m/z (MeOH) = 235.10 (MH+).
N,N-dimethyl-6-(naphthalen-1-yl)-5-(pyridin-4-
yl)pyridazin-3-amine (5a=MW181). Compound 4 (1.95 g,
8.5 mmol, 1 eq) and 1-naphthylboronic acid (1.96 g, 11.3 mmol,
1.37 eq) were suspended in dimethoxyethane (DME) and water
(10:1, v/v) in a heavy wall pressure vessel and purged with argon
for 15 min. Tetrakis (triphenylphosphine) palladium (0.860 g,
9 mol%) and Na2CO3 (2.7 g, 25.7 mmol, 3.1 eq) were added, the
vessel purged with argon and immediately capped with a Teflon
bushing, heated (110uC) for 17 hr, and cooled to ambient
temperature. The reaction mixture was subjected to filtration on
a medium frit sintered glass funnel containing CeliteH 545. The
resultant filtrate was concentrated in vacuo, the residue dissolved in
CH2Cl2, and subjected to water extraction (3630 ml) in a
separatory funnel. The organic layer was dried over anhydrous
sodium sulfate and concentrated by rotary evaporation under
reduced pressure. The crude mixture was subjected to silica gel
(200–400 mesh) column chromatography with product elution
using ethyl acetate: hexane (2:3 v/v). The product was crystallized
from hexane and ethyl acetate. Product 5a (MW181) was
obtained as light yellow crystals in 56% yield (gravimetric). HPLC
purity, 98%; ESI m/z (MeOH), 327.10 (MH+); MP = 189.5–
190uC (uncorrected); HRMS, 326.1526 (calculated for
C21H18N4 = 326.1531).
1H-NMR (CDCl3): 8.34 (d, J = 5.8Hz,
2H); 7.83(d, J = 8.2Hz, 2H); 7.68 (d, J = 8.4Hz, 1H); 7.42–7.26(m,
4H); 6.99 (dd, J = 1.5, 4.6, 2H); 6.84 (s, 1H); 3.33(s, 6H).
N,N-dimethyl-6-(naphthalen-2-yl)-5-(pyridin-4-
yl)pyridazin-3-amine (5b=MW108). Product 5b was pro-
duced using the protocol as above for 5a but using 2-
naphthylboronic acid (595 mg, 2.9 mmol, 1.37 eq) suspended in
DME:water mixture (10:1, v/v) The final product, 5b (MW-108)
was obtained as a whitish powder in 52% yield (gravimetric).
HPLC purity, 96%; ESI m/z (MeOH), 327.10 (MH+);
MP = 181.5–182uC (uncorrected); HRMS, 326.1538 (calculated
Figure 1. Discovery synthetic scheme for title compounds. Reagents and conditions: i) Hydrazine sulphate, H2O, 100uC; ii) Pyridin-4-ylboronic
acid; 1,2-dimethoxyethane (DME)/water, Na2CO3, Pd(PPh3)4, 110uC; iii) phosphorus oxychloride/acetonitrile, 90uC; iv) Ethanol, amine, reflux; v) 1- or 2-
Naphthylboronic acid, DME/water, Na2CO3, Pd(PPh3)4, 110uC; vi) concentrated HCl, anhydrous isopropanol, 80uC.
doi:10.1371/journal.pone.0066226.g001
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for C21H18N4 = 326.1531).
1H-NMR (CDCl3):
1H-NMR (CDCl3):
8.55 (d, J = 5.65 Hz, 2H); 7.93(s, 1H); 7.80–7.68 (m, 3H); 7.49–
7.34(m, 3H); 7.19 (d, J = 5.95Hz, 2H); 6.76 (s, 1H); 3.30(s, 6H).
Hydrochloride hydrate (6) of products 5a and 5b. This
was done as described [32]. Briefly, approximately 1 mmol of the
respective compound was suspended in 8.2 ml of anhydrous
isopropanol (99.5%, Aldrich), heated to 85uC with stirring until
dissolved, then 3.1 equiv (234ml) of concentrated ultrapure HCl
(12N, JT Baker UltrexH II, Product 6900-05) was added to the
clear solution, resulting in immediate generation of a suspension of
solids. The suspension was stirred for 10 min (80uC), allowed to
cool to ambient temperature, then the vessel placed on ice for
,2.5 h, then stored (,16 hr) at 4uC. The resulting yellow
precipitate was filtered on a medium frit sintered glass funnel
under vacuum, washed (3x) with cold anhydrous isopropanol
followed by three washes with cold anhydrous ether, and dried
under vacuum. The precipitate was stored in vacuo in a glass
desiccator containing silica gel until a constant weight was
attained. The final products were obtained in approximately
82% yield (gravimetric) compared to the starting material.
Hydrochloride hydrate formation was confirmed by elemental
analysis. The goal was to obtain a mole ratio of HCl:compound
that is .1. Under these conditions for the studies described here,
elemental analysis indicated a ratio of ,2. EA calculated for
C21H24Cl2N4O2 is: C, 57.94; H, 5.56; N, 12.87; Cl, 16.29; O,
7.35. Experimentally found for MW-181: C, 58.16; H, 5.60; N,
12.51; Cl, 16.52; O, 7.37. Experimentally found for MW-108: C,
56.09; H, 5.65; N, 12.38; Cl, 15.91; O, 10.16. Of special note is
the color of the final product, which is light yellow. A darker color
can be a potential indicator of non-organic impurities, such as the
presence of residual acid.
Chemical Characterization of Title Compounds MW108
and MW181
Aqueous solubility (logS) and chemical stability were deter-
mined as previously described [32]. Briefly, solutions for aqueous
solubility (log S) determination were made by gravimetric methods
using a Sartorius AG (Germany) BP 211 D analytical balance. Dry
borosilicate capillary tubes (Bu¨chi, Switzerland) were weighed and
various amounts of compound (ranging from 1.2–1.5 mg) or the
hydrochloride hydrate form (ranging from 10–20 mg) were added
to the tared tubes, then water added to create solutions ranging in
concentrations from 1–2 g/mL. Tubes containing the samples
were mixed to ensure wetting and incubated at 37uC for 24 h.
Aliquots were collected from each tube, centrifuged at 12,000 g-
min, and analyzed by HPLC. Concentrations were calculated
using area under the peak (260 nm) at the appropriate retention
time relative to a standard curve obtained from serial dilutions of
each purified compound. As an independent and extended control
evaluation of aqueous solubility, MW181 solubility was deter-
mined by CEREP, Inc. in simulated gastric fluid by the shake-flask
technique. Chemical stability was determined at a final concen-
tration of 0.0015 M at neutral (Milli-Q water), 0.1 N NaOH
(pH 13–14), 0.1 N HCl (pH 1–2) conditions with samples taken
for analysis at 3, 6, 24 h. As an independent and extended control
evaluation of chemical stability, MW181 solubility was determined
by CEREP, Inc in simulated gastric fluid at 37uC. The acid
dissociation constant (pKa) was determined by pION Inc.
(Billerica, MA) using both potentiometric and UV methods. The
co-solvent was methanol, experimental pH range was 1.7–10.0,
temperature was 2262uC, ionic strength was 0.15 M KCl. Five
titrations were used to calculate the pKa using the Yasuda-
Shedlovsky technique [33]. Quality control and calibrants used
were phosphate, 0.5 N KOH, 0.5 N HCl, and the FDA approved
drug flubiprofen (MW 244.2, PSA 37.3, cLogP 3.7). The screen for
ratio of peak concentration of orally administered MW108 or
MW181 in blood and brain was done as described previously
[31,32] using an oral gavage dose of 10 mg/kg body weight in
sterile saline. Processed samples from tissue extracts were acidified
with HPLC limit solvent and subjected to solid phase extraction
with elution done with 10% (v/v) acetonitrile into HPLC analysis
solvent A. The clinical CNS drug minaprine in its hydrochloride
hydrate formulation, in the same 3-amino-6-arylpyridazine
scaffold class as MW108 and MW181, was used as control and
internal standard.
Protein Kinase Inhibitor Activity
Concentration-dependent inhibition of protein kinase activity
was done essentially as previously described [31]. Assays had
calculated Z-factors $0.5 and %CV ,20%. Briefly, enzyme
activity assays were done with p38MAPK/SAPK2 and CK1c
enzymes (Millipore; Billerica, MA) and either the substrate myelin
basic protein (MBP, at 0.33 mg/ml for p38MAPKs) or the
substrate KRRRALS(p)VASLPGL (200 mM for CK1c) in either
25 mM Tris pH 7.5, 0.02 mM EGTA or in 50 mM HEPES,
pH 7.5, 5 mM MgCl2, 150 mM KCl, 15 mM NaCl, 1 mM DTT.
Reactions contained 100 mM ATP with c-[32P]ATP (specific
activity .300 cpm/pmol). Reactions were initiated by addition of
ATP substrate mix or the active enzyme. Reactions were stopped
by transfer of aliquots to P81 paper (Whatman, Clifton, NJ), and
the paper washed sequentially with 75 mM phosphoric acid and
95% ethanol. Quantification was done by scintillation counting.
Inhibitors were made as 10X stock solutions in DMSO or water,
and controls contained the same final concentration of solvent
added. Data are expressed as percent of the maximal enzyme
activity, where enzyme activity in the absence of compound is
taken as 100%. IC50 values are taken from the midpoint of a 10–
11 point curve of replicates that corresponds to 50% inhibition,
and were calculated using nonlinear regression curve fit analysis in
GraphPad Prism statistical software. The apparent Km for ATP
was determined by measuring kinase activity at six ATP
concentrations (10, 45, 90, 200, 500, 1000 mM) in the absence
of inhibitor. To estimate Ki values, these ATP concentrations
ranging from ten fold above and below the apparent Km for ATP
(approximately 100 mM) were used with increasing concentrations
of inhibitor to generate EC50 values taken from the midpoint of
the sigmoidal curves. The EC50 values were re-plotted against the
ATP concentration and the data fitted to a linear regression to
obtain the y-axis intercept, which is taken as the Ki.
Hierarchal Large-scale Kinome Analysis
Large-scale kinome screens were done using a hierarchal
screening protocol. First, an initial profiling was done with each
inhibitor tested at a fixed concentration (20,000 nM) in the
commercially available MilliporeH Profiler test systems (www.
millipore.com) that included .290 mammalian kinases represen-
tative of all major kinome branches as well as isoforms of
individual families. The list of protein and lipid kinases and their
NCBI Entrez accession numbers are provided in Tables S1 and
S2. Second, preliminary hits from the profiler screen (,40%
kinase activity remaining) were validated as true or false positive
hits by a follow-up, concentration-dependent test of the inhibitor
to obtain an IC50 value for the inhibitor and a given kinase. Third,
kinetic analyses were done as described above to determine a Ki
value on confirmed positives with IC50 values ,1,000 nM. The
full list of mammalian kinases, their NCBI database accession
identifier, the profiler screen results (% kinase activity remaining),
In Vivo Probes for CNS Protein Kinase Function
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and the IC50 from the concentration-dependent activity assays for
hits are provided for MW108 and MW181 in Tables S1 and S2.
Adverse Pharmacology and Off-target Functional Screens
Novel compounds were screened in vivo using a standard dose
escalation screen in mice coupled with clinical observation and
testing based on the SHIRPA mouse phenotype assay paradigm
[34]. To obtain insight into the potential for off-target activity with
the largest known family of small molecule drug targets, G-protein
coupled receptors (GPCRs), a cell-based functional screen of the
final title compounds was done. The MilliporeH GPCR Profiler
screen employs the ChemiScreen GPCR stable cell line technol-
ogy used for real-time calcium flux FLIPR assays on a panel of 158
GPCRs to detect both antagonists and agonists. The NCBI Entrez
identifier for each GPCR is provided at the vendor site (www.
millipore.com). Follow-up validation of any initial hits as being
true positives or negatives was done as described above for protein
kinases by testing the concentration dependence of any cellular
effects. No validated hits were detected.
Crystallographic Analysis of Human p38aMAPK in
Complex with Inhibitors
Human p38aMAPK with an amino terminal His6-tag was
produced by expression cloning in BL21(DE3)pLysS E. coli. After
recombinant DNA mediated insertion of the kinase cDNA (NCBI
Reference Sequence: NM_139012) region encoding amino acids
2–360 into the pMCSG7 expression vector at the SspI site,
transformed cells were selected with ampicillin (100 mg/ml) and
chloramphenicol (15 mg/ml), grown at 37uC until the A600 = 0.5,
then continued at 25uC for 14 hr after addition of isopropyl-b-D-
1-thiogalactopyranoside to a final concentration of 1 mM. Cell
pellets were collected by centrifugation (5100 g; 20 min), imme-
diately frozen at 220uC, rapidly thawed, and subjected to
sonication in buffer A (10 mM Tris pH 8.3, 0.5 M NaCl, 5 mM
b-mercaptoethanol) containing 10% (v/v) glycerol, 1mM pepstatin
A, 10 mM leupeptin, 1mM TLCK. All subsequent purification
steps were done at 4uC. The cell lysate was clarified by
centrifugation (39,000 g; 50 min) and the resultant supernatant
loaded onto a 5 ml HisTrapTM column (GE Healthcare, Cat.
No. 17-5248-01) equilibrated with buffer A. The column was
washed with 5 column volumes of buffer A containing 25 mM
imidazole, and step-elution of adsorbed protein done with buffer A
containing 0.5 M imidazole. The eluted protein was desalted by
passage through a HiPrep 26/10 column (GE Healthcare, Cat.
No. 17-5087-01) equilibrated with buffer B (10 mM Tris pH 8.3
and 5 mM b-mercaptoethanol) and subjected immediately to
chromatography on a 5 ml Q SepharoseTM High Performance
column (GE Healthcare, Cat. No. 17-1154-01) equilibrated with
buffer B. Column elution was done using a linear 80 mL gradient
from 0–0.5 mM NaCl in buffer B. Concentration of the protein
solution to 20 mg/ml in buffer B containing 150 mM NaCl was
done using a 10,000 MW cutoff concentrator (Vivascience/
Sartorius Cat. No. Vs2001, Aubagne, France). Protein concen-
tration was determined at A = 280 nm using a NanoDrop system
(Wilmington, Delaware, USA), and an extinction coefficient of
1.13 (mg/mL)-1cm-1. The protein solution was monodisperse
based on dynamic light scattering (Zetasizer Nanoseries Model
Zen1600, Malvern Instruments Ltd; Malvern, Worcestershire,
UK) done at 25uC and homogenous by SDS–PAGE. Protein was
stored at 280uC as flash frozen aliquots. Properties of frozen and
once thawed aliquots were indistinguishable from freshly prepared
protein solutions.
Protein samples for crystallization were prepared just before use
by adding an equal volume of 4 mM 4-(3-(4-fluorophenyl)-1H-
pyrazol-4-yl)pyridine (4-FPP; ASINEX-USA, Cat. No. LEG
22383617) in 8% (v/v) DMSO (Sigma, Cat. No. D-2650) to the
previously described p38aMAPK enzyme preparation (20 mg/ml
in buffer B containing 150 mM NaCl), and incubated for
approximately 45 min (4uC). Screening for crystallization condi-
tions was done with a commercially available kit (Classics II
screen; catalog No. 136165; Qiagen, Valencia, California, USA)
and the sitting drop method as previously described [35]. Visible
crystals were evident in less than 48 hrs at 22uC under conditions
of 0.1 M ammonium acetate, 0.1 M bis-tris pH 5.5, 17%(w/v)
PEG 10,000.
Formation of complexes with inhibitors MW181, MW108, and
SB239063 for crystallographic structure determination was done
using the crystal soak approach. Briefly, protein crystals were
transferred to individual wells of a PyrexH clear glass 9-well spot
plate (Cat. No. 7220–85; Corning MA) containing 0.1 M ammo-
nium acetate, 0.1 M bis-tris pH 5.5, 17%(w/v) PEG 10,000, and
inhibitor was added at a final concentration of 5 mM from a stock
solution of 50 mM in either saline (for MW181 and MW108) or
DMSO (for SB239063). The plate was covered with clear sealing
tape and incubated at ambient temperature. After three hours,
crystals were retrieved with a 20 micron 0.4 mm CryoLoop
(Hampton Research, CA) and flash frozen using liquid nitrogen
and 10% (v/v) glycerol as a cryoprotectant. The incubation time
was determined by evaluation of the active site occupancy by
ligand based on diffraction data. The structure was determined by
molecular replacement using the program PHASER and starting
model 3 HVC with ligands and waters removed. Iterative model
building was performed in Coot, refinement was performed with
REFMAC5, and solvent was added using ARP/wARP essentially
as previously described [35]. TLS refinement was applied for the
final model [36]. Coordinates, structure factors, and details of data
collection and processing are available in the protein data bank
(www.pdb.org) for the complexes of p38aMAPK with MW181,
MW108 and SB239063 under the accession codes 4F9Y, 4F9W
and 4FA2, respectively. In evaluating distances between ligand
and protein atoms, the NCONT program (CCP4 Program Suite
6.2.0,1994) was used. To measure distances from ring centers to
atoms, SYBYL-X v1.3 (Tripos International, Certera St. Louis,
MO) was used. A superposition of p38aMAPK complexes was
calculated by least squares fitting over all atoms.
Quantitative Cell-based Activity Screen
The ability of compounds to reduce stressor-induced up-
regulation of proinflammatory cytokine production was tested in
the murine microglial BV-2 cell line stimulated with LPS as
previously described [37]. For experiments, cells were plated in 48-
well tissue culture plates at 26104 cells/well and cultured for
24 hrs. Serum-containing medium was then removed and cells
were treated with either saline vehicle control or 100 ng/ml LPS
stimulus (LPS from Salmonella enterica serotype typhimurium;
EU/mg 600,000; Sigma Cat. No. L6143) in the absence or
presence of increasing concentrations of compound, with at least
six concentrations of compound ranging from 0.45 mM to 30 mM.
Stock solutions of compounds were made in sterile saline (0.9%
sodium chloride) that was free of preservatives (Hospira, Inc., Lake
Forest, IL: NDC 0409-4888-10). Solutions for cell treatments were
prepared by dilution of the stock solutions into serum-free media
immediately before adding to the cells. Compound was added to
cell cultures just before LPS addition. In some experiments, BV-2
cells were stimulated with other TLR ligands as described
previously [37]. TLR ligands used were TLR2:10 mg/ml LTA,
TLR4:100 ng/ml LPS, TLR7/8:500 ng/ml CL097, and
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TLR9:500 ng/ml ODN1668. Cells were harvested after 18 hrs of
treatment for cytokine measurements.
Levels of IL-1b in cell lysates were measured by ELISA using
kits from Meso Scale Discovery (MSD; Gaithersburg, MD), as
previously described [37]. For the most consistent cytokine
measurements with the lowest intra- and interassay variability,
cell lysates were frozen at 280uC for at least one hour, then
thawed prior to cytokine assay. Cytokine levels were determined
by comparison to standard curves ranging from 2.4 pg/mL to
10,000 pg/mL, and confirmation that sample values were on the
linear part of the standard curves. The levels of IL-1bwere
normalized to the LPS-stimulated vehicle-treated control group
for each 48-well tissue culture plate, with data presented as percent
of LPS alone. Data represent 3-to-10 independent experiments.
Cell-based Target Engagement and Activity
The concentration dependent ability of the compounds to
inhibit LPS-induced phosphorylation of MK-2, a highly selective
p38aMAPK substrate, was examined in BV-2 cells as previously
described [37]. BV-2 cells were plated in 48-well tissue culture
plates at 26104 cells/well and treated in serum containing media
with LPS in the absence or presence of compounds as described
above. After 60 min of treatment, cell lysates were prepared, and
phospho-MK-2 levels were measured by MSD ELISA kits. MSD
signal was baseline corrected by subtracting the un-stimulated
vehicle-treated control group. The data were then normalized to
the LPS-stimulated vehicle-treated control group for each 48-well
tissue culture plate. Data are presented as percent of LPS alone,
and represent 2-to-3 independent experiments.
The loss of inhibitory activity in LPS-induced microglia where
the endogenous p38aMAPK gene was disrupted by knock-in of a
fully active but drug resistant MAPK mutant, p38aT106M knock-in
[38], was tested in primary microglia cultures as previously
described [37]. Briefly, mixed glial cultures were prepared from
the cerebral cortex of 1–3 day old neonatal C57Bl/6 mice (WT)
or p38aT106M knock-in mice, and microglia were isolated from the
mixed glial cultures by the shake-off procedure as described [37].
Microglia were stimulated with LPS (3 ng/ml) or vehicle control
for 24 hrs in the absence or presence of inhibitors, and IL-1b levels
measured as described above. Data are expressed as a percent of
the maximal activity, where activity in the presence of LPS alone is
taken as 100%. Data represent 3 independent experiments.
Animal Ethics Statement
All experiments were conducted in accordance with the
principles of animal care and experimentation in the Guide For
the Care and Use of Laboratory Animals. The Institutional
Animal Care and Use Committees of the three universities
approved the use of animals in this study. For efficacy experiments,
3- to 4-month-old C57BL/6J male mice from a colony bred in the
Columbia University animal facility were used. At the University
of Kentucky, the in vivo LPS experiment was done with 2-month-
old, female, C57Bl/6J mice from Jackson Laboratory. The
p38aMAPK drug-resistant knock-in (p38aT106M) mice were
generated by replacement of Thr106 in p38a with Met as
previously described [38]. Remaining rodent studies were done at
Northwestern University as previously described [31,32].
In vivo Efficacy Related to CNS Inflammatory Response
The ability of compounds to inhibit an acute CNS inflamma-
tory response was tested in mice administered LPS to induce brain
cytokine production as previously described [37]. Briefly, 2-month
old, female, C57Bl/6 mice were administered LPS (0.5 mg/kg) by
i.p. injection and received compound (20 mg/Kg) or saline vehicle
by oral gavage in a volume of 200 mL one hr prior to the LPS
injection. At 6 hrs after LPS administration, mice were eutha-
nized, perfused with phosphate-buffered saline (PBS), and brain
cortex homogenate supernatants prepared as described [37]. IL-
1b levels in 50 mL of supernatant were determined by MSD
ELISA. BCA Protein Assay (Pierce) was used to normalize the
total amount of protein in the sample loaded.
In vivo Efficacy Related to Attenuation of Synaptic
Dysfunction
The ability of compounds to attenuate synaptic dysfunction
induced by toxic preparations of human Ab42 was examined by a
hierarchal approach as previously described [39]. The approach
includes an initial electrophysiological analysis in brain slices and a
subsequent in vivo screen using behavioral analyses.
Ab preparation. Ab42 was prepared as previously described
[40], starting from lyophilized peptide (American Peptide) that was
suspended in 100% 1,1,1,3,3,3-hexafluoro-2-propanol (Sigma-
Aldrich) and allowed to evaporate. The resulting clear peptide film
was stored at 20uC. Twenty-four hours prior to its use, the film was
suspended in DMSO (Sigma-Aldrich) and sonicated for 10 min.
This preparation was diluted into the bath solution, vortexed for
30 sec, and incubated at 4uC for 24 hrs. Western blot analysis was
routinely utilized to check the biochemistry of this aged synthetic
Ab.
Electrophysiological studies. Brain slices (400 mm) were
cut and maintained in an interface chamber at 29uC for 90 min
prior to recording, as previously described [40]. CA3-CA1
responses were recorded by means of a stimulating electrode, a
bipolar tungsten electrode, placed at the level of the Schaeffer
collateral fibers, and a recording electrode, a glass electrode filled
with bath solution. Following assessment of basal synaptic
transmission by plotting the stimulus voltages against slopes of
field EPSP, a 15 min baseline was recorded every minute at an
intensity that evokes a response ,35% of the maximum evoked
response. Then, LTP was evoked through a h-burst stimulation (4
pulses at 100 Hz, with the bursts repeated at 5 Hz and each
tetanus including three 10-burst trains separated by 15 sec). In
these experiments, 200 nM Ab42 or vehicle were perfused
through the bath solution for 20 min prior to application of the
h-burst, in the absence or presence of 10 mM MW181 or MW108.
Behavioral studies. A) Reference memory was studied with
the 2-day radial arm water maze (RAWM) as described [41].
Ab42 (200 nM, in a final volume of 1 ml over 1 min) or vehicle
were bilaterally infused 20 min prior to the 1st trial (for the 1st
group of tests of the RAWM) and 20 min prior to the 7th trial (for
the 2nd group of tests of the RAWM), into dorsal hippocampus of
mice that had been pre-implanted with a cannula the week before.
MW181 or MW108 (5 mg/Kg, i.p.) were administered 30 min
before the 1st and 2nd group of tests for the RAWM. As controls
for these experiments, visible platform testing was conducted to
exclude that visual, motor and motivation deficits affect the mouse
performance [39]. B) Fear conditioning to examine both
contextual and cued learning was performed as previously
described [42]. Ab42 was infused as above, 20 min prior to the
foot shock. Compounds were administered before training for fear
conditioning. For these experiments, threshold assessment test was
performed to check sensory perception of electric shock in
different groups of mice, as previously described [42]. In addition,
the open-field test was conducted to evaluate exploratory
behavior, as previously described [43].
In Vivo Probes for CNS Protein Kinase Function
PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e66226
Statistics
For activity screens, statistical analysis was conducted using
GraphPad prism software (GraphPad Software, San Diego
California USA). Calculations of IC50 values were made using a
nonlinear regression with a variable Hill slope, with the data
normalized to the positive control to fit the top and bottom
plateaus. Values are expressed as mean 6 SEM. Groups of 2 were
compared by unpaired T-test. Groups of 3 or more were
compared by One-way analysis of variance (ANOVA), followed
by Bonferroni Multiple Comparison Test. For efficacy studies, the
experiments were performed in blind (results expressed as mean 6
SEM). Significance of differences between 2 groups was
determined by t-test for pairwise comparisons or a 2-way ANOVA
with repeated measures for multiple comparisons. In all experi-
ments, significance was set at p,0.05.
Results
Design Strategy for Synthetic Refinement of p38aMAPK
Inhibitor Hit
The isoform-selective p38aMAPK inhibitor MW01-11-108
(MW108) and the p38MAPK subfamily inhibitor MW01-10-
181SRM (MW181) reported here were developed by structure-
and pharmacoinformatics-driven synthetic refinement of an initial
p38aMAPK inhibitor hit [31], MW01-2-069A-SRM (MW069a).
MW069a is a positional isomer of MW01-6-189WH [32], also
referred to as TT301 in clinical studies. While MW01-6-189WH
does not interact with p38MAPKs, MW069a binds to the active
site, as demonstrated by high-resolution co-crystallography (PDB
4EWQ), and is a novel, brain penetrant, p38MAPK inhibitor that
exhibits in vivo function in an AD mouse model [31]. However, the
MW069a hit had secondary kinase activity with p38bMAPK and
CK1d similar to other existing p38MAPK inhibitor reagents and
drugs in clinical development. Therefore, we used the high-
resolution crystal structure of 4EWQ as the starting point for
ligand design that was coupled with pharmacoinformatics
considerations to restrict syntheses to analogs with CNS drug-
like properties and low potential for CYP2D6 substrate status
[6,7].
Design, Synthesis and Chemical Properties of Novel and
Selective p38aMAPK Inhibitors Targeting the Active Site
The design, synthesis and molecular characterization of the
MW108 and MW181 title compounds reported here are
summarized in Materials and Methods, Results, Figures 2 and
3, Scheme S1, and Figure S1. The novel, brain penetrant
inhibitors are soluble, acidic, and chemically stable small
molecules targeted to the active site of p38aMAPK.
As is evident from Figure 2, the inhibitor structures are rule-of-
four compliant (i.e., MW,400, clogP,4, PSA,80A˚2), a multi-
property feature characteristic of most blood-brain barrier
penetrant small molecule drugs and in vivo probes [6,7]. The
experimental pKa determination values derive from two different
end points and reveal that the two inhibitors are acidic, consistent
with computed values of 3.0660.10 and the known properties of
modified pyridazines [44]. The experimental values for aqueous
solubility bracket the computed value of 4.9e-5 mol/L (pH 7.0) for
both structures. The commonly used HCl hydrate formulations
increase aqueous solubility significantly to , 0.4 and 0.8 mol/L
for MW108 and MW181, respectively. The results document that
the particular multi-aromatic system used in these chemical probes
is not likely to generate technical issues related to performance in
assays, and that the HCl hydrate form preferred for in vivo studies
will be readily soluble in aqueous buffers or physiological saline
solutions. Overall, the experimental results on physical properties
are consistent with the small molecule structures built around the
privileged pyridazine core used in clinical therapeutics and
preclinical in vivo research reagents.
The campaign started with a hit, MW01-2-069A-SRM, that is a
p38aMAPK inhibitor with in vivo CNS function. It emerged from
a structure-assisted, scaffold-reutilization design study based on a
clinically safe drug [31]. The co-crystal structure of the hit in
complex with human p38aMAPK (PDB 4EWQ) provided the
structure-based rationale for the ligand design (see Figure S1 for
diagram of design strategy). Previous synthesis and testing [31]
revealed a critical need for the pyridine substituent with its ring
nitrogen at the appropriate position and the need for an aryl
substituent at the R6 position on the pyridazine ring. Ligand
designs were filtered by pharmacoinformatics criteria based on
prior success in CNS drug discovery, with a focus on key physical
properties as a filter [6,7].
Several biology-relevant outcomes emerged during develop-
ment (Figure 3). Improvement of the no adverse effects levels
(NOAEL, the highest dose at which no adverse events are
observed in dose escalation studies) in mice emerged from
simplification of the amine at the R3 position of the pyridazine
core (e.g., inhibitors MW066, MW177, MW207, MW105), while
still retaining cross-over kinase inhibition. This is consistent with
neither the multi-kinase nature of inhibitors nor the target itself
being a major contributor to adverse events. While the reduced
size of the substituent at the R3 position improved pharmacolog-
ical properties in the in vivo screen, it resulted in loss of potential
ligand-protein interactions in this region of the structure.
However, the retention of p38aMAPK activity and acquisition
of improved safety with simplification of the R3 amine (as in
MW108 and MW181) allowed introduction of bulkier naphthyl
substituents at the R6 position, to better fill the hydrophobic
pocket, while remaining compliant with rule of 4 guidelines for
CNS penetrance [6,7]. The introduction of the 2-naphthyl
(MW108) or 1-naphthyl (MW181) substituent at R6 on the
pyridazine core was key to improvement of p38aMAPK affinity
and concomitant loss of CK1d affinity. Further, the presence of a
2-naphthyl in MW108 vs a 1-naphthyl in MW181 also resulted in
a loss of affinity for p38bMAPK and NLK with retention of
p38aMAPK affinity.
Kinase Profiling and Off-target Screens for Selectivity of
MW108 and MW181
Large-scale kinome screens of MW108 revealed only
p38aMAPK as a potential target (see Table S1). Follow-up
enzyme kinetics demonstrated a p38aMAPK Ki value of 114 nM
for MW108 (Figure 3, Figure S2). Large-scale kinome screens of
MW181 revealed p38aMAPK, p38bMAPK, and the atypical p38
kinase NLK as primary targets (see Table S2), with subsequent
kinetic analyses yielding Ki values, respectively, of 184 nM
(Figure 3, Figure S3), 322 nM and 199 nM. Noteworthy
overall is the lack of CK1d inhibition by either MW108 or
MW181, and the increased selectivity of MW108 for the
p38aMAPK isoform. In terms of the potential for unanticipated
off-target functions, both MW108 and MW181 were negative in
functional GPCR agonist and antagonist screens, and neither
compound revealed adverse pharmacology in mice at the highest
dose tested (Figure 3; 200 mg/kg, 10–40 fold higher than in vivo
doses used in efficacy screening assays). Both compounds were
CNS penetrant, as assessed by the brain/blood peak ratio after
oral administration. This composite profile qualified the novel
inhibitors for further biological and structural analyses.
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High-resolution Co-crystal Structures of Compounds with
Human p38aMAPK
To confirm the active site targeting of MW108 and MW181
and test prevailing hypotheses, we determined the high-resolution
co-crystal structures of human p38aMAPK in complex with the
two selective inhibitors. As summarized in Figure 4, both
inhibitors occupy the active site, engage the hinge region peptide
backbone at Met109, and occupy the nearby hydrophobic pocket.
The structures and the associated crystallographic data are
deposited and available in the Protein Data Bank under accession
numbers 4F9W (containing MW108) and 4F9Y (containing
MW181). A summary of key diffraction data fitting statistics is
provided in Table 1. Both complexes clearly exhibit the DFG-in
motif notation used widely in protein kinase conformation
analyses, although this is no longer used as a conformational
change that correlates with or forecasts inhibitor activity [15].
Importantly, neither compound induced a hinge region glycine
flip.
The high-resolution co-crystallography results raised the ques-
tion of why we were able to generate such a selective inhibitor that
lacked a localized conformational change assumed to be a key
factor in generating selectivity [16–30]. To address if our
experimental protocol could detect such localized conformation
changes, we performed a control crystallographic study of
Figure 2. Characterization of selective p38aMAPK inhibitors MW108 (panel A) and MW181 (panel B). The title compounds were
characterized in terms of their physical characteristics, target selectivity, and pharmacological properties.
doi:10.1371/journal.pone.0066226.g002
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p38aMAPK in complex with SB239063. SB239063 is represen-
tative of a widely used class of p38aMAPK inhibitors that are
mixed kinase inhibitors, with activity against both CK1d and
p38MAPKs. The crystallization and formation of the complex as
well as data collection and processing were done as performed for
the p38aMAPK complexes with MW108 and MW181. The
resultant structure and the associated crystallographic data for the
human p38aMAPK in complex with SB239063 are available in
the Protein Data Bank under accession identifier 4FA2. Superpo-
sition analyses using least squares fitting revealed conformational
similarity among the three structures (4F9W, 4F9Y, 4FA2) except
for the deviation of 4FA2 from the other two conformations in the
hinge region of the kinase. The well-defined crystallographic data
in the hinge region demonstrates a difference in the peptide bond
between Met 109 and Gly 110 in the 4FA2 complex compared to
4F9W and 4F9Y (Figure 5). Specifically, the alpha carbon (Ca) of
Gly 110 differs by 1.89 A˚ and the carbonyl oxygen of Met 109 is
displaced by 2.81 A˚. This observation correlates with repositioning
of the protein backbone conformation referred to as the glycine-
flip. The control 4FA2 results demonstrate that such a conforma-
tional change can be detected in human p38aMAPK by the
methods used for 4F9W and 4F9Y, but these latter structures do
not manifest the alternative conformation. Further, the results with
the control 4FA2 complex demonstrate that the glycine flip
conformational change in p38aMAPK does not correlate with
selectivity for p38aMAPK.
CNS Mechanism of Action and Linkage to a
Pharmacodynamic End Point
The ability of MW108 to engage its target in a cellular assay was
done by examining the concentration-dependent inhibition of
phosphorylated MK-2, considered a highly selective p38aMAPK
substrate. Figure 6A shows the results with the microglial cell line
BV-2 stimulated with the standard glial activating stimulus
lipopolysaccharide (LPS). There is a clear decrease in phosphor-
ylated MK-2 in LPS-stimulated cells with increasing concentration
of MW108. LPS activation of the signal transduction pathway
involving p38aMAPK and its substrate MK-2 results in a
downstream increase in proinflammatory cytokine production.
Therefore, we quantified the levels of the proinflammatory
cytokine interleukin 1b (IL-1b) as a function of MW108
Figure 3. Synthesis of p38aMAPK inhibitor analogs and initial screens for differential p38aMAPK vs CK1d inhibition and for
improvement in high dose tolerance. The affinity of compounds for p38aMAPK and CK1d is shown, as well as the highest dose at which no
adverse events are observed in dose escalation studies.
doi:10.1371/journal.pone.0066226.g003
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concentration (Figure 6B), and showed a coincident decrease
over a similar concentration range. The IC50 using inhibition of
IL-1b overproduction as an end point was 610620 nM.
To extend the general biological relevance of the initial cellular
engagement studies, we examined the ability of MW108 to inhibit
increases in IL-1b levels using different stressors, wild-type and
inhibitor resistant primary cells, and in vivo responses. As shown in
Figure 6C, the inhibition of IL-1b production is not limited to
LPS as a stressor, but was also seen in BV-2 cells stimulated with
diverse TLR ligands (TLR2, TLR4, TLR7/8, TLR9). As shown
in Figure 6D, further validation was provided by demonstrating a
loss of MW108 activity in primary microglia cultures where the
endogenous p38aMAPK was removed by targeted knock-in
replacement with a fully active but drug resistant mutant
p38aT106MMAPK. The knock-in yields catalytically normal
kinase, but the replacement of the gatekeeper Thr at residue
Figure 4. Crystal structures of human p38aMAPK with MW108 (PDB 4F9W) or MW181 (PDB 4F9Y) bound in the active site. A. The
2.00A˚ structure (4F9W) of human p38aMAPK (cyan ribbons) containing MW108 (colored by atom type) bound in the active site is shown. The typical
kinase bi-lobed nature is evident, with the hinge region connecting the two lobes of the kinase indicated by the arrow. B. A Connolly surface
generated from the coordinates of 4F9W highlights the complementary features between MW108 and the kinase active site. C. Electron density map
(2mFo-Dfc) for 4F9W contoured at a 1.5 rmsd level. The diffraction data clearly reveals the inhibitor presence in the active site. The relative positions
of Met 109 in the hinge region and the hydrophobic pocket’s small gatekeeper residue Thr 106 are indicated by arrows. The pyridine ring nitrogen of
MW108 makes H-bond interactions with the protein backbone at the Met109-Gly110 peptide bond. D. The 1.85A˚ resolution structure (4F9Y) of
human p38aMAPK (cyan ribbons) with MW181 (colored by atom type) bound in the active site is shown, with the hinge region indicated by the
arrow. E. A Connolly surface generated from the coordinates of 4F9Y highlights the complementary features between MW181 and the kinase active
site. F. Electron density map (2mF0-Dfc) for 4F9Y contoured at 1.5 rmsd. The difference in orientation of the1-naphthyl substituent in MW181 4F9Y
from that of the 2-naphthyl substituent in MW108 4F9W (Panel C) is evident from the diffraction data.
doi:10.1371/journal.pone.0066226.g004
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106 with a larger side chain Met amino acid renders the mutant
p38aT106MMAPK resistant to inhibitors such as MW108 that
exploit the use of the hydrophobic pocket with bulky substituents
such as a naphthyl group. To probe the in vivo relevance of the
proinflammatory cytokine modulation seen in glia cultures, we
tested if oral administration of MW108 could attenuate stressor
induced IL-1b increases in the brain. As shown in Figure 6E, oral
administration of MW108 restored IL-1b levels in the brain cortex
back towards control. Altogether, these results demonstrate that
MW108 engages its molecular target p38aMAPK and modulates
the linked cellular response of increased proinflammatory cytokine
production, and that this target-related function is evident in vivo.
A prevailing hypothesis in kinase inhibitor development based
on analysis of successful drug development campaigns is that in vivo
efficacious kinase inhibitors engage a close set of multiple kinases
[15]. Relatedly, many existing p38aMAPK inhibitors are equiv-
alent or better inhibitors of other p38MAPK family members (e.g.,
p38bMAPK and NLK) or unrelated kinases with convergent
active site folds (e.g., CK1). To address whether a p38MAPK
inhibitor that inhibits other p38MAPK family members, but lacks
CK1 inhibition, would have cellular activities similar to MW108,
we examined the quantitative activity of MW181. MW181
exhibited activities similar to MW108, including inhibition of
increased cytokine production by glia in response to LPS
(IC50 = 820630 nM) and other TLR ligands, inhibition of MK-
2 phosphorylation, loss of activity in drug resistant microglia, and
in vivo suppression of increased brain levels of IL-1b after oral
administraton (Figure 7). The data indicate that the activity and
function of the p38MAPK family inhibitor, MW181, probably
reflects its p38aMAPK inhibition in these assays.
In vivo Efficacy following Amyloid-beta Elevation
We have previously documented in multiple AD-relevant
animal models [31,45–47] that proinflammatory cytokine over-
production is an early event in the progression of AD pathophys-
iology that is causally linked to synaptic dysfunction and cognitive
deficits. In addition, p38aMAPK has been implicated as a
contributor to AD-relevant pathology progression [4]. However,
we are not aware of an in vivo assay precedent for a single kinase
inhibitor being functional in such a CNS disorder model.
Therefore, we used a hierarchal evaluation of whether MW108
could attenuate synaptic dysfunction and cognitive impairments.
To assess synaptic function, we used the widely studied long-
term potentiation (LTP) experimental model of synaptic plasticity.
We induced LTP in the presence of oligomeric Ab42, a peptide
that accumulates in the brains of AD patients. As expected from
previous studies [39–42,48], Ab reduced LTP (Figure 8A).
Importantly, MW108 ameliorated the Ab-induced electrophysio-
logical deficit (Figure 8A), indicative of rescue of synaptic
plasticity impairment.
The initial results were extended by testing whether MW108
could attenuate cognitive deficits in two AD-relevant behavioral
tasks that measure two types of memory dysfunction: the radial
arm water maze (RAWM) to measure reference memory [41] and
fear conditioning to measure contextual fear memory [42]. Ab42
or vehicle was bilaterally infused into the dorsal hippocampus of
mice. Ab-infused mice showed memory deficits, exhibiting more
performance errors compared to vehicle-infused mice (Figure 8B).
Treatment with MW108 rescued the memory defects (Figure 8B).
In the fear conditioning task, Ab42 caused a contextual fear
memory deficit which was prevented by MW108 administration
(Figure 8C). Control experiments, including visible platform test,
open field, sensory threshold assessment and cued learning,
showed no differences across groups (Figure 8D-I). These data
document that MW108 attenuates AD-relevant impairments in
synaptic plasticity and memory.
Similar results were obtained with MW181. Specifically,
MW181 was efficacious in rescuing the LTP deficit and the
behavioral impairments in RAWM and fear conditioning tasks,
with no differences across groups seen in the control experiments
(Figure 9). Overall, the data document that an isoform selective
p38aMAPK inhibitor is efficacious at reducing AD-relevant
synaptic and functional impairments, and that mixed p38MAPK
family member inhibitors that lack CK1d and other cross-over
inhibitor activities can, under appropriate conditions, be surro-
gates for the isoform selective inhibitor.
Table 1. Data collection and phasing statistics. Values in
parentheses are for highest resolution shell.
4F9W
(MAPK-108)
4F9Y
(MAPK-181)
4FA2
(MAPK-
SB239063)
Data Collection
Space group P212121 P212121 P212121
Wavelength (A˚) 0.97872 0.97856 0.97872
Cell dimensions a,b,c
(A˚)
65.6, 74.3, 77.2 66.5, 74.8, 78.2 65.1, 74.1, 77.7
Resolution (A˚) 30.00–2.00 50.00–1.85 30.00–2.00
Outer Resolution Shell
(A˚)
(2.03–2.00) (1.88–1.85) (2.03–2.00)
Completeness (%) 99.9 (99.9) 99.9 (99.9) 99.9 (100.0)
Rmerge 0.075 (0.678) 0.039 (0.537) 0.059 (0.440)
Mean I/s(I) 24.5 (2.5) 42.4 (3.8) 30.8 (4.8)
Redundancy 6.1 (5.7) 7.3 (7.3) 7.3 (7.4)
No. of Unique
Reflections
26189 34190 26070
Refinement
statistics
Resolution (A˚) 29.80–2.00 33.76–1.85 29.81–2.00
Rwork 0.17 (0.22) 0.16 (0.21) 0.17 (0.18)
Rfree 0.21 (0.26) 0.20 (0.26) 0.21 (0.25)
Residues 336 339 339
Atoms
Protein 2769 2913 2873
Ligand 25 25 27
Waters 186 314 185
Mean B-value (A˚2)
Overall 35.1 29.0 31.1
Protein 40.6 36.6 38.4
Ligand 32.2 34.9 30.6
Waters 45.1 43.5 45.0
RMSD bond lengths
(A˚)
0.012 0.012 0.012
RMSD bond angles (o) 1.50 1.36 1.33
Ramachandran plot, %
Most Favored 97.6 97.3 97.9
Allowed 2.1 2.4 2.1
Generously Allowed 0.3 0.3 0.0
Disallowed 0.0 0.0 0.0
doi:10.1371/journal.pone.0066226.t001
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Discussion
The studies reported here provide precedents and insight for
targeting serine-threonine kinases for CNS investigations, and
demonstrate the potential of brain p38aMAPK as a target for
modulating progression of synaptic dysfunction. First, we demon-
strate that targeting the active site ATP-fold of protein kinases is a
more viable approach for the discovery of highly selective kinase
inhibitors with in vivo functional utility than is generally assumed.
Our findings provide insight that should be useful in future kinase
inhibitor design, and raise caution about exuberance over
hypotheses driven by observations on localized conformational
changes that do not correlate with experimental data from kinase
inhibitor activity profiles. Second, the results demonstrate that an
isoform-selective inhibitor of a CNS kinase target can be
efficacious in vivo. This revises the assumption that in vivo efficacy
requires appropriate targeting of multiple discrete kinases. Third,
adverse pharmacology did not correlate with inhibitor cross-over
to other p38MAPK isoforms or to the distinct CK1d kinase.
MW108, MW181, and the intermediate inhibitors generated
during refinement all lack frank adverse pharmacology at higher
doses observed with MW069a, yet they vary in their kinase
inhibitor selectivity among p38MAPK isoforms and CK1d.
Fourth, the combination of cellular and in vivo observations
reported here implicate the p38aMAPK isoform as a quantitative
contributor to CNS stress-related responses and as a molecular
target whose inhibition can attenuate synaptic dysfunction. As a
potential CNS target, p38aMAPK is especially attractive due to its
key roles in both glial and neuronal processes, offering the
potential for a more robust in vivo inhibition under certain stress
related responses. Currently, there are no selective p38aMAPK
inhibitors in CNS clinical trials. However, the impact on
attenuation of synaptic dysfunction suggests the potential of this
kinase as a potential drug discovery target. While the novel in vivo
chemical probes described here are not drugs or drug candidates,
their drug-like properties and pharmacodynamics make them
logical starting points for drug discovery studies that must be done
to optimize structures and meet FDA recommendations and
standard practices in preclinical drug development. Their current
biological utility is predominately as small molecule neuroscience
research tools to address essential issues, such as biological time
windows for effective intervention, and the extension of in vivo
pathology progression investigations to other animal species.
The high-resolution crystal structures of human p38aMAPK
with either MW108 (4F9W) or MW181 (4F9Y) bound in the active
site confirm the design features of the discovery platform and
provide a starting point for future explorations of the molecular
basis of small molecule recognition by p38aMAPK and its
extension to other kinase-chemical probe paradigms. For example,
the chemical probes and structural insights reported here provide
an immediate starting point for exploration of the high-resolution
co-crystal structures of active site-directed ligands with greater
selectivity for p38bMAPK or CK1d in order to understand the
molecular basis of selective ligand-kinase target recognition
between these two branches of the kinome and, by extension, to
related protein folds emerging from structural genomics investi-
gations.
While our results are not consistent with kinase selectivity being
correlated with a localized induction of a glycine flip conforma-
tional change, it is possible for the core pyridazine ring to
participate in such an interaction. The pyridazine ring differs from
other diazines, such as pyrimidines, due to the different atomic
environment provided by two contiguous nitrogen atoms in an
aromatic ring and is less acidic in nature, thereby allowing
different roles for the pyridazine ring nitrogens depending on the
its molecular context in a scaffold [49]. For example, both of the
pyridazine ring nitrogens have the potential to engage in H-bond
interactions with the Met109-Gly110 peptide backbone to stabilize
Figure 5. Localized conformational change in the hinge region of human p38aMAPK when a non-selective inhibitor is bound. A.
Electron density maps (2mFo-Dfc; colored in light gray) contoured at 1.5 rmsd for the hinge region of p38aMAPK near Gly110 for 4F9W (in complex
with MW108) and for 4FA2 (in complex with SB239063) are shown. Differences in the electron density path are seen in the area around Gly110,
indicated by arrows. B. A superposition of 4F9W and 4FA2 reveals the differences around the peptide bond at Met109-Gly110, referred to as a glycine
flip for structures such as 4FA2.
doi:10.1371/journal.pone.0066226.g005
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a flipped glycine conformation [50] when in the context of a fused
benzopyridazine ring system (phthalazine). However, when the
pyridazine ring is a core chemotype diversified with a pyridine,
which has a single nitrogen atom with even greater basicity than
pyridazine ring nitrogens, the pyridine ring nitrogen would be
Figure 6. Cellular target engagement and mechanism of action
of MW108. A. MW108 inhibited phosphorylation of the p38a
substrate MK2 in a concentration-dependent manner in LPS-stimulated
BV-2 microglial cells. B. MW108 inhibited LPS-induced IL-1b production
in a concentration-dependent manner in BV-2 cells. C. MW108
suppressed IL-1b production in BV-2 cells stimulated with diverse TLR
ligands. BV-2 cells were treated with ligands for TLR2, TLR4, TLR7/8, and
TLR9 in the absence (white bars) or presence (gray bars) of MW108. `
p,0.0001 compared to TLR ligand in the absence of compound. D.
MW108 inhibited LPS-induced IL-1b production in primary microglia
from wild-type (WT) mice, but not from drug-resistant p38aMAPK
knock-in (p38a KI) mice. # p,0.01, 1 p,0.001 compared to LPS alone.
E. MW108 suppressed LPS-induced IL-1b levels in vivo. **p,0.01
compared to LPS alone (n = 6 saline/vehicle; n = 24 LPS/vehicle;
n = 15 LPS/MW108). Data in all panels are expressed as a percent of
the maximal levels, where levels in the presence of stressor alone were
normalized to 100%.
doi:10.1371/journal.pone.0066226.g006
Figure 7. Cellular target engagement and mechanism of action
of MW181. A. MW181 inhibited phosphorylation of the p38aMAPK
substrate MK2 in a concentration-dependent manner in LPS-stimulated
BV-2 microglial cells. B. MW181 inhibited LPS-induced IL-1b production
in a concentration-dependent manner in BV-2 cells. C. MW-181
suppressed IL-1b production in BV-2 cells stimulated with diverse TLR
ligands. BV-2 cells were treated with ligands for TLR2, TLR4, TLR7/8, and
TLR9 in the absence (white bars) or presence (gray bars) of MW181. `
p,0.0001 compared to TLR ligand in the absence of compound. D.
MW181 inhibited LPS-induced IL-1b production in primary microglia
from wild-type (WT) mice, but not from drug-resistant p38aMAPK
knock-in (p38a KI) mice. # p,0.01, 1 p,0.001 compared to LPS alone.
E. MW181 suppressed LPS-induced IL-1b levels in vivo. **p,0.01
compared to LPS alone (n = 6 saline/vehicle; n = 24 LPS/vehicle;
n = 15 LPS/MW181). Data in all panels are expressed as a percent of
the maximal levels, where levels in the presence of stressor alone were
normalized to 100%.
doi:10.1371/journal.pone.0066226.g007
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Figure 8. Attenuation of Ab42-induced synaptic and cognitive dysfunction by MW108 administration. A. MW108 ameliorated the LTP
deficit in Ab42-treated slices (n = 7–8 slices/group; F(1,13) = 17.25, p = 0.0011, compared to slices treated only with Ab42). Horizontal bar = time of
application of Ab42 and MW108. B. MW108 ameliorated the reference memory deficit in Ab42-infused mice (n = 10–14 mice/group; F(1,24) = 1.827,
p = 0.0001 comparing Ab-infused vs. Ab-infused+compound). C. MW108 ameliorated the contextual fear memory deficit in Ab42-infused mice (n = 16-
18 mice/group; p = 0.009 comparing Ab-infused vs. Ab-infused+compound). D-E. No difference was detected between groups when tested for
visual-motor-motivational deficits with the visible platform test; speed and time to the platform are shown in D and E, respectively (n = 10–14 mice/
group). F. The same animals that underwent contextual fear conditioning testing were assessed for cued learning 24 hrs after the contextual
learning. No difference was detected between groups (n = 16–18 mice/group). G. Sensory threshold was not affected regardless of treatment (n = 13–
17 mice/group). H-I. No differences in exploratory behavior, as shown by a similar percentage of time spent in the center compartment (H) and the
number of entries into the center compartment (I), were observed (n = 13–17 mice/group).
doi:10.1371/journal.pone.0066226.g008
Figure 9. Attenuation of Ab42-induced synaptic and cognitive dysfunction by MW181 administration. A. MW181 ameliorated the LTP
deficit in Ab42-treated slices (n = 7–8 slices/group; F(1,13) = 6.651, p = 0.0229, compared to slices treated only with Ab42). Horizontal bar = time of
application of Ab42 and MW181. B. MW181 ameliorated the reference memory deficit in Ab42-infused mice (n = 10 mice/group; F(1,18) = 5.851,
p = 0.0264 comparing Ab-infused vs. Ab-infused+compound). C. MW-181 ameliorated the contextual fear memory deficit in Ab42-infused mice
(n = 15–16 mice/group; p = 0.0005 comparing Ab-infused vs. Ab-infused+compound). D-E. No difference was detected between groups when tested
for visual-motor-motivational deficits with the visible platform test; speed and time to the platform are shown in D and E, respectively (n = 10 mice/
group). F. The same animals that underwent contextual fear conditioning testing were assessed for cued learning 24 hrs after the contextual
learning. No difference was detected between groups (n = 15–16 mice/group). G. Sensory threshold was not affected regardless of treatment
(n = 9 mice/group). H-I. No differences in exploratory behavior, as shown by a similar percentage of time spent in the center compartment (H) and
the number of entries into the center compartment (I), were observed (n = 9 mice/group).
doi:10.1371/journal.pone.0066226.g009
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favored for protein H-bond interactions. This is what is observed
in 4F9W and 4F9Y. Therefore, the pyridazine ring has the
potential to be exploited as a biologically friendly fragment for
kinase inhibitor development with either the potential to H-bond
with the hinge region in a bidentate manner, thereby generating a
glycine flip conformational change if the kinase is one of the few
containing the appropriate sequence in the hinge region space, or
the pyridazine ring can also be exploited as a molecular fragment
placed in the context of a more basic substituent that forces the
pyridazine ring to serve a different ligand role, such as a
framework for diversifications that allows sampling of alternative
space within kinases as observed in 4F9W and 4F9Y. The latter
use of the pyridazine chemotype is not restricted to the localized
sequence criteria so it is potentially more generalizable to other
kinase targets. In either ligand role, the attractive biodistribution of
pyridazine based molecular probes in complex biological systems
is possible, depending on the molecular properties of the final
ligand, as this aspect of pyridazines is a component of pharma-
cokinetics prior to target binding and engagement.
In conclusion, this report describes the development of selective
chemical probes for in vivo studies of p38aMAPK and their use to
demonstrate p38aMAPK is a key contributor to synaptic
dysfunction and is amenable to therapeutic intervention. In
addition, the insight gained from our co-crystallography studies
under standardized conditions provides a foundation for future
investigations of molecular recognition by small molecule probes
and protein kinases.
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